Cancer breakthrough!

Intensive care medicine is one of the most fast growing segments in medicine. New substances that may improve therapy of the critically ill dramatically have entered the market. Improvements include therapy of methicilline-resistant Staphylococcus aureus (MRSA) infections (linezolid), severe heart failure (calcium sensitizer levosimendan), intractable bleeding (recombinant factor VIIa) and severe sepsis (recombinant activated protein C (aPC)). The anticipations concerning this new strategies of intensive care therapy are high, but use of the new substances is associated with extreme costs. In the past, pharmaceutical therapy represented only a small aspect of all costs in the intensive care unit (ICU). Using this new substances, we are entering a new dimension of costs. One case of recombinant factor VIIa or recombinant aPC increases costs by approximately 10000,- Euro. At the moment, this costs are not covered by extra-budgets. It is still unclear whether by using this new therapeutic strategies other costs can be reduced and the extreme extra-costs can be balanced. The elderly population will increase dramatically in the next years. Looking at this development, it is not only the question whether we can afford intensive care medicine, but the question has to be enlarged whether we can afford the new developments of intensive care medicine. All responsible persons (intensivists, pharmaceutical companies, politicians) are urged to define solutions in the near future.

Can we afford the costs of new developments in intensive care medicine? Dtsch Med Wochenschr. 2004 Jan 2;129(1/2):36-40. PMID: 14703580

Bottom line?

It's the bottom line that determines the quality of your healthcare - whether your provider is your government or a private health insurance company.

Chronic disease is the budget killer. Most epidemic chronic diseases are linked to pollution - and prevention involves a global clean-up.

It's not happening. So back to the money markets, reinsurance industry - and "cost-effective treatment strategies."

Translation? Let them eat, drink and breathe poison, get sick, and then withhold effective treatment because it's too expensive and not "cost-effective.

Originally posted by soficrow
Health care costs are rising world wide. Most of these costs are new, associated with new drug developments. Budgets in socialized medical insurance systems are stressed to the breaking point, and governments have responded by developing "cost-effective treatment strategies." The European approach refers....

It's the bottom line that determines the quality of your healthcare - whether your provider is your government or a private health insurance company.

Chronic disease is the budget killer. Most epidemic chronic diseases are linked to pollution - and prevention involves a global clean-up.

It's not happening. So back to the money markets, reinsurance industry - and "cost-effective treatment strategies."

Translation? Let them eat, drink and breathe poison, get sick, and then withhold effective treatment because it's too expensive and not "cost-effective."

Originally posted by FatherLukeDuke

Even the link between something like asthma and pollution isn't clear.

Originally posted by bsl4doc

Also, I don't know where you got the idea my links were by "big pharma giants" ?? They were from the Universities of Torino and Milano, not exactly pharmaceutical companies so much as universities that are known for biomedical research. Try again.

A relatively few risk factors – high cholesterol, high blood pressure, obesity, smoking and alcohol – cause the majority of the chronic disease burden.
A change in dietary habits, physical activity and tobacco control, have a major impact in reducing the rates of these chronic diseases, often in a relatively short time.

A few, largely preventable, risk factors account for most of the world’s disease burden. Chronic diseases are the major cause of death and disability worldwide, and increasingly affect people from developing as well as developed countries. This reflects a significant change in diet habits, physical activity levels, and tobacco use worldwide as a result of industrialization, urbanization, economic development and increasing food market globalization.

Noncommunicable conditions, including cardiovascular diseases (CVD), diabetes, obesity, cancers and respiratory diseases, account for 59% of the 57 million deaths annually and 46% of the global burden of disease. Half of these (17 million annually) are CVD, the majority heart disease and stroke. Five of the top 10 selected global disease burden risk factors identified by World Health Report 2002: reducing risks, promoting healthy life - obesity, high blood pressure, high cholesterol, alcohol and tobacco – independently and often in combination, are the major causes of these diseases.

The scientific evidence is strong that a change in dietary habits and physical activity can powerfully influence several of these risk factors in populations. Recognising this, WHO is adopting a broad-ranging approach and has begun to formulate a Global Strategy on Diet, Physical Activity and Health, under a May 2002 mandate from the World Health Assembly (WHA).This extensive, population-wide, prevention-based strategy will be developed over the next two years and presented to the WHA in 2004.

This will become the strategic backbone for WHO and its Member States to work together with other stakeholders in promoting global changes towards healthier diets and increased physical activity, to prevent chronic diseases and promote population health. who.int

The research was conducted through the universities - and funded by big pharma.

Originally posted by soficrow

Originally posted by FatherLukeDuke

Even the link between something like asthma and pollution isn't clear.

Scientists have pinpointed a gene which has been found to be a major cause of asthma in a significant proportion of cases.
news.bbc.co.uk...


Please visit the link provided for the complete story.

Genetic factors: asthma tends to run in families, and many people with asthma also have other allergic conditions such as rhinitis (inflammation of the nose lining). "Allergy" is a hypersensitivity to some proteins foreign to the body: a small dose of the "allergen" will produce a violent reaction in the person concerned.

Environmental factors: in wealthy, hygienic Western countries, most babies are not exposed to bacterial infections that "kick start" the immmune system in early life and may be important in directing the immune system away from allergic responses. They also grow up in warm, well-furnished, carpeted homes that don't allow much airflow. This encourages the rapid breeding of large numbers of house dust mites in bedding, carpets and furnishings. Many children, instead of playing outside in fresh air, spend most of their time indoors. This further increases dust mite sensitisation. Exposure to tobacco smoke, whether during the mother's pregnancy or in early childhood, predisposes children to developing asthma. It also makes their symptoms more severe. Children can also become sensitised to animals, pollens moulds and dust in the environment if they are genetically predisposed.

Dietary changes: changes in diet in Western countries, such as a high proportion of processed foods, a higher salt intake, a lower antioxidant intake and a lack of fresh oily fish (lower intake of omega-3 fatty acids) may contribute to the development of asthma.

Lack of exercise: spending more time inside in front of the television means that children get far less exercise. Reduced exercise may mean less stretching of the airways, and a greater tendency for the muscle in the airway walls to contract abnormally when exposed to minor irritants.

Occupational exposure: in adults, asthma can develop in response to irritants in the workplace - chemicals, dusts, gases, moulds and pollens. These can be found in industries such as baking, spray painting of cars, woodworking, chemical production, and farming.

www.healthinsite.gov.au...


Please visit the link provided for the complete story.

The World Health Organisation (WHO) estimates that 388 million people in the world will die from chronic disease in the next 10 years."

About Antigenics

Antigenics’ mission is to enhance and extend human lives through the development of superior health care products for a wide range of cancers, infectious diseases, and autoimmune and degenerative disorders. The company’s cancer portfolio includes Oncophage®, a personalized cancer vaccine in Phase III trials and on the US Food and Drug Administration’s fast track development program for kidney cancer and melanoma; and two liposomal products in Phase II development: Aroplatin™, a third-generation platinum chemotherapeutic, and ATRA-IV, a form of vitamin A. Other products in development include QS-21, an immune adjuvant being tested in several advanced clinical vaccine programs in partnership with leading pharmaceutical companies, and AG-702, a genital herpes immunotherapeutic agent in Phase I testing.

The jury in Gadsden, Ala., a town 20 miles from Anniston, yesterday held Monsanto and its corporate successors liable on all six counts it considered: negligence, wantonness, suppression of the truth, nuisance, trespass and outrage. Under Alabama law, the rare claim of outrage typically requires conduct "so outrageous in character and extreme in degree as to go beyond all possible bounds of decency so as to be regarded as atrocious and utterly intolerable in civilized society."

Originally posted by bsl4doc

The research was conducted through the universities - and funded by big pharma.

WRONG, source please.

Pevion Biotech is a privately owned biopharmaceutical company focusing on the development of vaccines for the
treatment and prevention of infectious diseases, cancer and neurodegenerative disorders.

Current alliances and collaborations: University of Siena, Italy...

***

[Chiron is legendary in terms of bad vaccines and its links to the Bush administration. Check out Chiron's links with Italian universities and some cancer vaccine marketing details.]

Chiron Italy Media Kit

***

December 2001 - March 2002: short-term fellowship at the University of Padova, Italy (Sponsor: GlaxoSmithKline, Verona, Italy). Research project: Molecular dynamics simulations of a protein-ligand complex of the P24 fragment of GyraseB with its inhibitor GR122222.
Bio-computing

***

Chemical Computing Group develops and markets MOE, the Molecular Operating Environment, a leading application for chemical researchers in the pharmaceutical and biotechnology fields. Its built-in applications cover the spectrum of drug discovery including: Protein/Homology modeling, High Throughput Screening, Combinatorial Library Design, Modeling/Simulations and Methods Development. MOEs unique architecture and platform independence allows it to be used corporate-wide by a variety of researchers - from methods developers to computational experts to medicinal chemists. Its customers include a worldwide roster of leading pharmaceutical and biotechnology companies.
Molecular Modeling Section Department of Pharmaceutical Sciences University of Padova,

John Cabot University, a regionally accredited US four-year college located in Rome, Italy, invites applications for the position of Director for Development and Institutional Advancement.

The Director will work in close collaboration with the University President and Board of Trustees to plan and execute all phases of a comprehensive campaign and will be asked to assist the President in leading the institution through significant capital campaigns and in piloting ongoing efforts to improve all aspects of the University's development operations.

Specific responsibilities will include development and coordination of annual and long-range strategic fund-raising plans, budget preparation and forecasting analysis, foundation administration and grant writing, as well as oversight and management of the identification, cultivation, solicitation and stewardship of annual and major gifts to the University from individuals, corporations and foundations. Superior organizational and writing skills are essential, as are a commitment to high performance and teamwork, a strong work ethic, and an understanding of the vital importance of higher education in an increasingly interdependent and multicultural world.

The successful candidate will possess a proven record of fund-raising success, preferably in higher education, with extensive experience in soliciting major gifts, and a drive to achieve ambitious institutional goals.

Corporate and Foundation Relationships: Director for Development and Institutional Advancement

Pollution is now only considered one of the triggers to asthma, and not it's root cause:

The root cause is probably mercury poisoning.....as it is the root cause of many, many things.

Originally posted by bsl4doc

Why would the same companies you suggest are covering up a cure want to fund cure research? Seems a bit daft. Or stupid.

About Antigenics

Antigenics’ mission is to enhance and extend human lives through the development of superior health care products for a wide range of cancers, infectious diseases, and autoimmune and degenerative disorders. The company’s cancer portfolio includes Oncophage®, a personalized cancer vaccine in Phase III trials and on the US Food and Drug Administration’s fast track development program for kidney cancer and melanoma; and two liposomal products in Phase II development: Aroplatin™, a third-generation platinum chemotherapeutic, and ATRA-IV, a form of vitamin A. Other products in development include QS-21, an immune adjuvant being tested in several advanced clinical vaccine programs in partnership with leading pharmaceutical companies, and AG-702, a genital herpes immunotherapeutic agent in Phase I testing.

The jury in Gadsden, Ala., a town 20 miles from Anniston, yesterday held Monsanto and its corporate successors liable on all six counts it considered: negligence, wantonness, suppression of the truth, nuisance, trespass and outrage. Under Alabama law, the rare claim of outrage typically requires conduct "so outrageous in character and extreme in degree as to go beyond all possible bounds of decency so as to be regarded as atrocious and utterly intolerable in civilized society."

quote: Originally posted by bsl4doc

Why would the same companies you suggest are covering up a cure want to fund cure research? Seems a bit daft. Or stupid.




Or very, very profitable.

Posted this earlier - guess you and lukeduke missed it.

Shows the link between Monsanto, a company that makes products that cause cancer, and Antigenics, a company that sells cancer 'cures.' ...Continued exposure to cancer triggers of course ensures 'recurrence,' and return sales.

Originally posted by bsl4doc

I just can't stand how people like you and excitable seem to characterize all doctors as these evil money grubbers.

Please quote exactly what I said that "characterized all doctors as evil money grubbers."

FYI - the rising costs of medical treatments are breaking budgets around the world, particularly in nations with socialized medicine. The preferred solution is to withhold new treatments, and also, to withhold the information that those treatments do, in fact, exist. You will note that most of the researchers quoted recommend early diagnosis and intervention to prevent disease progression and the inevitable array of costs associated with severe disease - these pleas remain unheard.

t's not happening. So back to the money markets, reinsurance industry - and "cost-effective treatment strategies."

Translation? Let them eat, drink and breathe poison, get sick, and then withhold effective treatment because it's too expensive and not "cost-effective."

This is really basic stuff. Here's the poop:

1. Research is very expensive.
2. Drug and vaccine development is even more expensive.
3. So universities - in Italy and elsewhere - rely on corporate funding and sponsorships.
4. In turn, the universities lend corporations expertise, facilities and a much-needed aura of legitimacy and scientific rigour.